European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia : vimarsana.com

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment -

...

Related Keywords

Boston , Massachusetts , United States , France , London , City Of , United Kingdom , Australia , Rome , Lazio , Italy , America , Reshma Kewalramani , Franco Locatelli , European Union , Catholic University Of The Sacred Heart , Exchange Commission , Vertex Pharmaceuticals Incorporated Nasdaq , Department Of Pediatric Hematology , European Commission , Youtube , Linkedin , Companies To Work , Vertex Pharmaceuticals Incorporated , Chief Executive Officer , Catholic University , Sacred Heart , Pediatric Hematology , Bambino Ges , Sickle Cell Disease , Transfusion Dependent Beta Thalassemia , Conditional Marketing Authorizations , North America , Latin America , Top Employers , Private Securities Litigation Reform Act , Markets ,